Merlin Capital LLC Vertex Pharmaceuticals Inc Transaction History

Merlin Capital LLC

  • $32.2 Million
  • Q1 2024

A detailed history of Merlin Capital LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Merlin Capital LLC holds 2,027 shares of VRTX stock, worth $949,264. This represents 2.63% of its overall portfolio holdings.

Number of Shares
2,027
Previous 1,982 2.27%
Holding current value
$949,264
Previous $806,000 5.09%
% of portfolio
2.63%
Previous 2.37%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$407.69 - $446.08 $18,346 - $20,073
45 Added 2.27%
2,027 $847,000
Q4 2023

Feb 05, 2024
SELL
$343.0 - $410.68 $10,290 - $12,320
-30 Reduced 1.49%
1,982 $806,000
Q3 2023

Nov 13, 2023
SELL
$338.18 - $362.46 $9,807 - $10,511
-29 Reduced 1.42%
2,012 $699,000
Q2 2023

Aug 10, 2023
SELL
$314.42 - $351.91 $242,732 - $271,674
-772 Reduced 27.44%
2,041 $718,000
Q2 2023

Aug 09, 2023
BUY
$314.42 - $351.91 $163,812 - $183,345
521 Added 22.73%
2,813 $793,000
Q1 2023

May 15, 2023
SELL
$283.23 - $323.1 $13,028 - $14,862
-46 Reduced 1.97%
2,292 $722,000
Q4 2022

Feb 13, 2023
SELL
$285.76 - $321.48 $30,290 - $34,076
-106 Reduced 4.34%
2,338 $675,000
Q3 2022

Nov 14, 2022
SELL
$273.83 - $305.53 $101,043 - $112,740
-369 Reduced 13.12%
2,444 $708,000
Q2 2022

Jul 20, 2022
SELL
$234.96 - $292.55 $51,926 - $64,653
-221 Reduced 7.28%
2,813 $793,000
Q1 2022

May 16, 2022
SELL
$221.42 - $260.97 $209,684 - $247,138
-947 Reduced 23.79%
3,034 $792,000
Q4 2021

Mar 14, 2022
BUY
$177.01 - $223.45 $704,676 - $889,554
3,981 New
3,981 $874,000

Others Institutions Holding VRTX

# of Institutions
1,707
Shares Held
226M
Call Options Held
1.2M
Put Options Held
1.59M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Merlin Capital LLC Portfolio

Follow Merlin Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Merlin Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Merlin Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email